AstraZeneca (AZN) Lowered to “Neutral” at Bryan, Garnier & Co

AstraZeneca (LON:AZN) was downgraded by research analysts at Bryan, Garnier & Co to a “neutral” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also weighed in on the stock. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, October 9th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Friday, September 7th. Jefferies Financial Group reissued a “hold” rating and set a GBX 5,800 ($75.79) price target on shares of AstraZeneca in a research report on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, August 30th. Finally, Citigroup reissued a “buy” rating and set a GBX 6,200 ($81.01) price target on shares of AstraZeneca in a research report on Tuesday, September 25th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and an average target price of GBX 5,831.89 ($76.20).

Shares of AZN stock opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Why do company’s buyback their stock?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit